Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons

Received for publication, February 22, 2015, and in revised form, March 30, 2015. Published, JBC Papers in Press, April 13, 2015, DOI 10.1074/jbc.M115.646885

Letizia Palomba1,2, Cristoforo Silvestri1, Roberta Imperatore1, Giovanna Morello1, Fabiana Piscitelli1, Andrea Martella1, Luigi Cristiano1, and Vincenzo Di Marzo1

From the 1Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino 61029, Italy and 2Endocannabinoid Research Group, 3Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli 80078, Italy

Background: In hypothalamic neurons, leptin induces ROS production via PPAR-γ inhibition.

Results: CB1 agonism prevents leptin-induced ROS accumulation by reversing PPAR-γ and catalase inhibition. Inhibition of endocannabinoid inactivation also counteracts leptin effects.

Conclusion: CB1 inhibits effects of leptin that underlie part of its anorexigenic actions.

Significance: During conditions of increased endocannabinoid tone CB1 might reduce leptin activity in the hypothalamus.

The adipocyte-derived, anorectic hormone leptin was recently shown to owe part of its regulatory effects on appetite-regulating hypothalamic neuropeptides to the elevation of reactive oxygen species (ROS) levels in arcuate nucleus (ARC) neurons. Leptin is also known to exert a negative regulation on hypothalamic endocannabinoid levels and hence on cannabinoid CB1 receptor activity. Here we investigated the possibility of a negative regulation by CB1 receptors of leptin-mediated ROS formation in the ARC. Through pharmacological and molecular biology experiments we report data showing that leptin-induced ROS accumulation is 1) blunted by arachidonyl-2'-chloroethanolamide (ACEA) in a CB1-dependent manner in both the mouse hypothalamic cell line mHypoE-N41 and ARC neuron primary cultures, 2) likewise blocked by a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, troglitazone, in a manner inhibited by T0070907, a PPAR-γ antagonist that also inhibited the ACEA effect on leptin, 3) blunted under conditions of increased endocannabinoid tone due to either pharmacological or genetic inhibition of endocannabinoid degradation in mHypoE-N41 and primary ARC neuronal cultures from MAGL−/− mice, respectively, and 4) associated with reduction of both PPAR-γ and catalase activity, which are reversed by both ACEA and troglitazone. We conclude that CB1 activation reverses leptin-induced ROS formation and hence possibly some of the ROS-mediated effects of the hormone by preventing PPAR-γ inhibition by leptin, with subsequent increase of catalase activity. This mechanism might underlie in part CB1 orexigenic actions under physiopathological conditions accompanied by elevated hypothalamic endocannabinoid levels.

1 Present address: Dept. of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.
2 To whom correspondence should be addressed: Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, Comprensorio Olivetti, 80078, Pozzuoli (NA), Italy. Tel: 39-081-8675018; Fax: 39-081-8041770; E-mail: vdimarzo@icb.cnr.it.

3 The abbreviations used are: EC, endocannabinoid; ECS, endocannabinoid system; ACEA, arachidonyl-2'-chloroethanolamide; AEA, anandamide; 2-AG; 2-arachidonoylglycerol; ARC, arcuate nucleus; DHR, dihydrorhodamine 123; FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; PPAR-γ, peroxisome proliferator-activated receptor-γ; ROS, reactive oxygen species; ANOVA, analysis of variance.
Endocannabinoids Inhibit Leptin Function in the Hypothalamus

proliferation of peroxisomes mediated by a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist resulted in the decrease of ROS levels. ROS are a group of highly reactive molecules, such as singlet oxygen, hydroxyl radicals, superoxide, and hydrogen peroxides. Most ROS have extremely short half-lives (nanoseconds), whereas some others, such as hydrogen peroxide, have millisecond half-lives. Due to their high reactivity, ROS can oxidize cell constituents such as lipids, proteins, and DNA, thus damaging cell structures and compromising their function (6). Because of these potentially noxious effects, cells maintain ROS at a tolerable level by means of antioxidants such as the reduct system, superoxide dismutase, and catalase (7). Catalase, predominantly located in peroxisomes, catalyzes the conversion of hydrogen peroxide into water and molecular oxygen (8). The transcription of this enzyme is regulated by PPAR-γ. A putative functional PPAR response element was identified at the promoter region of the rat catalase gene (9). Activation of PPAR-γ by a specific agonist further enhances catalase activity and protects neurons from oxidative stress (10). Growing evidence indicates that endocannabinoids exhibit profound anti-inflammatory and neuroprotective properties in response to harmful insults, including oxidative stress (11–15). Some of these effects appear to be mediated by PPAR-γ activation (16–18).

The present study was designed to investigate whether leptin-induced ROS formation could be controlled by activation of CB1 receptors in hypothalamic neurons. We report that in a mouse hypothalamic neuronal cell line (mHypoE-N41) as well as in primary cultures of hypothalamic neurons, ACEA, a selective CB1 receptor agonist, is able to prevent ROS formation induced by leptin in a manner sensitive to AM251, a CB2 receptor antagonist/inverse agonist, and through PPAR-γ activation and subsequent enhancement of catalase activity. Furthermore, by using pharmacological tools and knock-out mice, we show that CB1 inhibition of leptin-induced ROS formation is exerted tonically by ECs in hypothalamic neurons.

Experimental Procedures

Cell Cultures—mHypoE-N41 cells were cultured in Dulbecco’s modified Eagle’s medium (Life Technologies) supplemented with 10% horse fetal bovine serum (Life Technologies), penicillin (50 units/ml), and streptomycin (50 μg/ml) at 37 °C in 100-mm culture dishes (Life Technologies) gassed with an atmosphere of 95% air, 5% CO2.

Experimental Procedures

Cnr1 Gene Silencing—Cnr1 silencing was obtained by transfecting mHypoE-N41 cells with endoribonuclease-prepared siRNA sequences (EMU088771; Sigma) using Lipofectamine 2000 (Life Technologies) and following the manufacturer’s instructions. The siRNA silencing efficiency was determined 24 h after the initial transfection by measuring mRNA levels (data not shown) or the relative amount of the protein using Western blot analysis.

Detection of CB1 Receptors—Immunocytochemical and Western blot techniques were used to detect the expression of CB1 receptor protein. For immunocytochemical analysis, primary cultures of hypothalamic ARC neurons were seeded on polylysine-coated coverslips, washed 3 times with PBS, and finally fixed for 20 min with paraformaldehyde (4%; v/v). These preparations were then rinsed with PBS and blocked in PBS-containing BSA (2%, w/v). The rabbit polyclonal anti-CB1 (Calbiochem) or mouse monoclonal anti-NuN (Abcam) antibody was used as a primary antibody. After 18 h at 4 °C, the cells were washed and exposed to a fluorescein isothiocyanate-conjugated secondary antibody for 2 h in the dark. Stained cells were analyzed with a Leica DMI6000 fluorescence microscope equipped with a Leica DFC320 cooled digital CCD camera (Leica Microsystems).

For Western blot analysis mHypoE-N41 cell homogenate was subjected to electrophoresis in 10% polyacrylamide gel and transferred to PVDF membranes. Membranes were blocked with 3% BSA for 1 h and incubated overnight at 4 °C with a rabbit polyclonal anti-CB1 antibody (Calbiochem; 1:1000 dilutions) or with a polyclonal anti-actin (1:1000, Sigma), whereas incubation with the secondary antibody (peroxidase-labeled) was for only 2 h. Actin was taken as the reference protein expression. Detection was performed using ECL Western blotting detection reagents (GE Healthcare Italia).
Measurement of 2-AG and AEA Levels—After treatment, the cells (each data point contained 1 × 10⁵ and 0.5 × 10⁵ cells/ml for N41 and primary neurons, respectively) and supernatant were homogenized in 50 mmol/liter Tris-HCl, pH 7.5, in chloroform/methanol (1:2:1, v/v) containing 10 pmol of [2H₈]AEA and 5 pmol of 2-[3H]2-AG as internal standards and analyzed using liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry as previously described (20). 2-AG and AEA levels were calculated on the basis of their peak area ratio (in the SIM mode) with the internal deuterated standard peak areas, and their amounts (pmol) were normalized per ml of cells plus medium.

Catalase Activity—Catalase activity was measured using an Amplex Red Catalase Assay kit (Life Technologies) following the manufacturer’s instructions. Briefly, cells treated as detailed in the figure legend were washed twice with PBS, scraped on ice, and finally sonicated 3 times with a Branson Sonifer operating at 20 watts for 15 s. The resulting homogenates were centrifuged for 5 min at 18,000 × g at 4 °C. The supernatant was used to measure catalase activity. The decomposition of hydrogen peroxide (40 μM) by catalase was monitored by reaction with 50 μM Amplex red reagent in the presence of 0.2 unit/ml horseradish peroxidase. Fluorescence was measured in a fluorescence microplate reader using excitation at 530 nm and emission at 590 nm. Catalase activity was normalized to protein concentration, which was quantified by the Lowry protein assay.

PPAR-γ DNA Binding Activity—The DNA binding activity of PPAR-γ was assayed using a commercially available PPAR-γ transcription factor assay kit (Abcam) according to the manufacturer’s instructions. Briefly, the nuclear extracts prepared from treated cells were added to the provided wells coated with specific oligonucleotide sequences. A primary polyclonal anti-PPAR-γ antibody was then added followed by the addition of horseradish peroxidase-conjugated antibody and the substrate 3,3′,5,5′-tetramethylbenzidine. The absorbance of the developed color was read at 450 nm using a microplate reader.

Results

CB₁ Receptor Activation Mitigates Leptin-induced ROS Formation in mHypoE-N41 Cells and in Primary Cultures of Hypothalamic ARC Neurons—Recently, it was reported that the mechanism whereby leptin produces its anorexic effects might involve ROS formation in ARC neurons (5). We used DHR, a cell-permeable fluorogenic probe that is useful for the detection of ROS formation, to determine if the treatment of murine hypothalamic mHypoE-N41 cells with increasing concentrations of leptin results in ROS accumulation. As shown in Table 1, mHypoE-N41 cells express high levels of CB₁ receptor mRNA together with the mRNAs encoding for the major biosynthetic enzymes of the ECS, including the anandamide hydrolyzing enzyme, fatty acid amide hydrolase-1 (FAAH-1), the anandamide biosynthesizing enzyme, N-acylphosphatidylethanolamine-specific phospholipase D, and the 2-AG biosynthesizing enzyme, diacylglycerol lipase-α. Very low levels of CB₂ receptor mRNA and MAGL were instead found. As illustrated in Fig. 1A, a 4.5-h treatment with leptin induced a dose-dependent formation of ROS with the maximum effect at 100 ng/ml. The leptin (100 ng/ml) response was reduced by pre-exposure for 15 min to ACEA, a specific CB₁ receptor agonist, in a dose-dependent manner (Fig. 1B). The inhibitory effect of ACEA (0.5 μM) was abolished by treating the cells with AM251 (0.5 μM), a CB₁ receptor antagonist/inverse agonist (Fig. 2A). In the same experimental conditions, treatment with AM630, a CB2 receptor antagonist, was ineffective. Similar results were obtained using 2′,7′-dichlorofluorescein diacetate, another fluorogenic probe to detect ROS formation (data not shown). In vivo studies have demonstrated that the accumulation of ROS induced by leptin were mitigated by the proliferation of peroxisomes, induced by PPAR-γ activation (5). This might be the case also for mHypoE-N41 cells treated with leptin, because, as shown in Fig. 2, a short pre-exposure (15 min) to troglitazone (1 μM), a PPAR-γ agonist, prevented the formation in a manner sensitive to T0070907, a specific PPAR-γ antagonist. It is important to note that in the same experimental conditions, T0070907 also abolished the inhibitory effect of ACEA on leptin. Accordingly, mHypoE-N41 cells express high levels of the mRNA encoding for PPAR-γ but not PPAR-α (Table 1). Interestingly, leptin-induced ROS formation, although insensitive to heat-inactivated catalase, was prevented by enzymatically active catalase (10 unit/ml; Fig. 2A). These findings are, therefore, consistent with the possibility that H₂O₂ is the major reactive molecule produced by the cells after treatment with leptin. Additionally, both ACEA and troglitazone were also able to prevent the H₂O₂-induced DHR oxidation. Again the inhibitory effect of ACEA was prevented by both AM251 and T0070907 but not by AM630 (Fig. 2B).

The results obtained with leptin were confirmed in primary cultures of ARC neurons. Using immunocytochemical techniques, we detected the expression of CB₁ receptors in these cells (Fig. 3A). Leptin was able to induce ROS formation in primary neurons (Fig. 3, B and C), and again, this effect was prevented by both ACEA (Fig. 3, B and C) and troglitazone (Fig. 3C) in a manner sensitive, in the case of ACEA, to AM251 (Fig. 3, B and C), and in the case of both compounds by T0070907 (Fig. 3C).

To provide further evidence that the effect of ACEA was due to CB₁ activation, experiments were performed in mHypoE-N41 cells transfected with CB₁ receptor-specific siRNA sequences. These cells showed an ~50% decrease (measured by Western blot assays) in CB₁ expression with respect to cells transfected with a scrambled siRNA control (Fig. 4A), which in

### Table 1

| Genes     | Ct    |
|-----------|-------|
| Pparg     | 25.67 |
| Ppara     | 35.19 |
| Mgl       | 31.90 |
| Dagla     | 25.66 |
| Nape-PLD  | 25.94 |
| Cer1      | 27.88 |
| Cer2      | 30.09 |
| Faah-1    | 26.76 |

Endocannabinoids Inhibit Leptin Function in the Hypothalamus

Real-time quantitative PCR results from mHypoE-N41 cells cultured in standard growth medium to 90% confluence in 24-well plates. Data are expressed as threshold cycle (Ct), and S.D. of reactions performed in triplicate. DAGL-α, diacylglycerol lipase-α; NAPE-PLD, N-acylphosphatidylethanolamine-specific phospholipase D.
Endocannabinoids Inhibit Leptin Function in the Hypothalamus

FIGURE 1. The CB₁ receptor agonist ACEA prevents leptin-induced ROS formation in mHypoE-N41 cells. A, DHR-loaded cells were incubated for 4.5 h with increasing concentrations of leptin. After treatments, the cells were observed with a Leica DMI6000 fluorescence microscope equipped with a Leica DFC320 cooled digital CCD camera (Leica Microsystems). The resulting images were analyzed to quantify the mean fluorescence of individual cells using Metamorph Imaging Software (Leica MetaMorph AF). Representative micrographs of the dose-dependent inhibition of ROS formation are also shown. Scale bar: 20 μm. Results are expressed as arbitrary units and represent the means ± S.E. calculated from three to five separate experiments, each performed in duplicate. *, p < 0.01 compared with untreated cells; (**), p < 0.01 compared with leptin-treated cells (one-way ANOVA followed by Bonferroni’s test).

FIGURE 2. A CB₁, as well as a PPAR-γ agonist reduces leptin (A)- or H₂O₂ (B)-induced DHR oxidation in mHypoE-N41 cells. DHR-loaded cells were incubated with AM251 (0.5 μM), AM630 (1 μM), or T0070907 (1 μM). After 30 min, cells were exposed to ACEA (0.5 μM) or troglitazone (1 μM) for an additional 30 min and, finally, treated with leptin (100 ng/ml; 4.5 h) or H₂O₂ (0.1 mM; 4.5 h). In other experiments the cells were incubated with catalase (10 unit/ml; 30 min) or boiled catalase and then treated with leptin (100 ng/ml; 4.5 h). After treatments, the cells were analyzed with a fluorescence microscope as described in Fig. 1A. Results represent the mean ± S.E. of three separate experiments, each performed in duplicate. *, p < 0.05; **, p < 0.01 compared with untreated cells; (+), p < 0.05; (**) p < 0.01 compared with leptin-treated cells (one-way ANOVA followed by Bonferroni’s test).

Turn displayed levels of CB₁ expression identical to those observed in non-transfected cells (not shown). As shown in Fig. 4B, in CB₁ siRNA-transfected cells, ACEA failed to prevent leptin-induced ROS formation, and this lack of effect was not modified by AM251.

A CB₁-mediated Tone of ECs Controls Leptin-induced ROS Formation and Is under the Negative Control of EC Hydrolyzing Enzymes—2-AG is the most abundant EC in the brain (21–23) where it is hydrolyzed primarily by MAGL (24). Pharmacological or genetic inhibition of MAGL results in an increase of 2-AG levels in the brain (25, 26). To provide evidence for a tonic action of ECs on leptin-induced ROS formation and because mHypoE-N41 cells express only very low levels of MAGL (Table 1), we adopted a dual experimental strategy: 1) to investigate the role of AEA, we treated mHypoE-N41 cells with a selective FAAH-1 inhibitor, URB597, and 2) we performed experiments in primary cultures of hypothalamic neurons isolated from wild-type or MAGL null mice; neurons from the former mice were also investigated in the presence of a selective MAGL inhibitor, JZL184. As shown in Fig. 5A, in mHypoE-N41 cells, URB597 (1 μM) reproduced the effects described above with ACEA in terms of the AM251-sensitive inhibition of leptin-induced ROS formation and induced a significant increase of basal activation of CB₁ by high levels of 2-AG in these neurons as compared with wild-type mouse neurons (Table 2). Accordingly, the treatment with increasing concen-
Concentrations of AM251 restored the leptin-induced ROS formation. These data strongly suggest that ECs may tonically inhibit leptin-induced ROS formation, at least in vitro, and that this inhibition is under the negative control of EC degrading enzymes.

**PPAR-γ Activation by CB1 and Its Impact on Leptin-induced ROS Formation in mHypoE-N41 Cells**—To provide additional evidence of the involvement of PPAR-γ activation in ROS inhibition by ACEA, we measured PPAR-γ DNA binding activity in the above experimental conditions. As shown in Fig. 6A, a 4.5-h treatment of mHypoE-N41 cells with leptin (100 ng/ml) resulted in the reduction of PPAR-γ activity. This response was prevented by preincubation with both ACEA and troglitazone. T0070907 alone resulted in the decrease of PPAR-γ activity.
The Effect of CB₁ Activation on Leptin-induced ROS Formation Is Due to PPAR-γ-mediated Catalase Activation—It is well known that PPAR-γ regulates a large number of enzymes, including catalase, the most important enzyme for antioxidant defense. We, therefore, investigated the effect of leptin on catalase activity. As illustrated in Fig. 6B, exposure of cells to 100 ng/ml leptin for 4.5 h resulted in a reduction of catalase activity. Under the same conditions, a pretreatment with ACEA (15 min) as well as troglitazone prevented this effect in a manner sensitive to both AM251 and T0070907, respectively (Fig. 5B). It is important to note that ACEA alone was able to increase catalase activity. Taken together, these results strongly suggest that the mechanism whereby ACEA counteracts leptin-mediated ROS formation involves PPAR-γ activation and subsequent activation of catalase.

Discussion

The results reported in the present study establish for the first time the existence of a negative control by CB₁ receptor activation over an action by leptin, i.e. the capability of the hormone to elevate ROS levels in hypothalamic neurons, which is emerging as an important signal mediating leptin anorectic effects. We found that in both mHypoE-N41 cells and primary cultures of hypothalamic ARC neurons, leptin was able to induce ROS formation (Figs. 1–3) and that this effect was blunted by ACEA, a specific CB₁ receptor agonist, in a manner sensitive to AM251, a CB₁ receptor antagonist/inverse agonist. The CB₁-mediated mechanism of action of ACEA was further confirmed using CB₁ siRNA-mediated knockdown in mHypoE-N41 cells. We also report the mechanism whereby CB₁ receptors control leptin action. In fact, it was recently demonstrated that the ROS-mediated anorexic effect of leptin can be counteracted by the induction of peroxisome proliferation mediated by PPAR-γ activation. The latter effect occurs also in our experimental conditions, as a PPAR-γ agonist, troglitazone, was able to prevent leptin-mediated ROS formation in both mHypoE-N41 cells and in primary hypothalamic neurons. As expected, the effect of troglitazone was prevented by the pretreatment with T0070907, a PPAR-γ antagonist. The observa-
Endocannabinoids Inhibit Leptin Function in the Hypothalamus

TABLE 2

AEA and 2-AG levels in leptin-treated mHypo-E-N41 cells and in primary hypothalamic neurons

Endogenous levels of AEA and 2-AG were quantified by LC-atmospheric pressure chemical ionization-MS in mHypo-E-N41 cells treated with leptin (100 ng/ml) with or without URB597 (1 μM) or in primary cultures of hypothalamic neurons isolated from C57BL/6 or MAGL null mice. AEA and 2-AG levels are normalized per ml of cell + medium. Each sample contained 1 × 10^{-1} and 0.5 × 10^{-5} cells/ml for N41 and primary neurons, respectively. Results represent the means ± S.E. of three separate experiments and were compared by using ANOVA followed by Bonferroni’s test.

|                   | AEA (pmol/ml) | 2-AG (pmol/ml) |
|-------------------|---------------|----------------|
| **mHypo-E-N41 cells** |               |                |
| Untreated         | 0.15 ± 0.05   | 2.91 ± 0.55    |
| Leptin            | 0.20 ± 0.01   | 3.13 ± 0.005   |
| Leptin + URB597   | 0.89 ± 0.04*  | 2.43 ± 0.31    |
| **Primary hypothalamic neurons** |          |                |
| Wt Untreated      | 0.07 ± 0.01   | 5.51 ± 0.26    |
| Wt Leptin         | 0.04 ± 0.01   | 11.23 ± 0.54*  |
| Wt Leptin + URB597| 0.12 ± 0.03   | 11.45 ± 0.96*  |

* p > 0.05.

FIGURE 6. Effect of CB1 activation on leptin-induced decrease of PPAR-γ and catalase activity in mHypo-E-N41 cells. Cells were incubated with AM251 (0.5 μM) or T0070907 (1 μM). After 30 min, the cell were exposed to ACEA (0.5 μM) or troglitazone (1 μM) for an additional 30 min and, finally, treated with leptin (100 ng/ml; 4.5 h). After treatments, the cells were analyzed for both PPAR-γ (A) and catalase (B) activity as described under “Experimental Procedures.” Results represent the mean ± S.E. of three separate experiments, each performed in duplicate. *, p < 0.05; **, p < 0.01 compared with untreated cells; (*), p < 0.01 compared with leptin-treated cells (one-way ANOVA followed by Bonferroni’s test).

In agreement with the present findings in neurons, the activation of CB1 receptors was previously shown to lead to overexpression of PPAR-γ in adipocytes (30, 31). The underlying mechanism of this effect has never been investigated, but it is possible that the well known CB1-induced activation of ERKs might cause phosphorylation of C/EBPβ (32), a transcription factor that activates PPAR-γ, thus explaining why ACEA enhances PPAR-γ activity also in hypothalamic neurons, which express C/EBPβ. Indeed, we have found that the effects of ACEA were inhibited by the MAPK inhibitor PD098059 (data not shown). However, ACEA differs from AEA only in the presence of a chlorine atom on the 2-carbon atom of the ethanolamine moiety, and it possible that, like AEA (as well as other cannabinoids; for review, see Ref. 33), it also directly activates PPAR-γ.

Importantly, we have also shown that in the cell model mostly used in our experiments, the mHypo-E-N41 cells, not only are CB1 receptor mRNA and protein-expressed, but also the mRNAs encoding the enzymes responsible for EC biosynthesis and hydrolytic inactivation (except for MAGL) are abundant. This finding is in keeping with our data indicating that endogenous AEA might exert, under the negative control of FAAH-1, a CB1-mediated inhibitory tone on leptin-induced ROS stimulation in mHypo-E-N41 cells and in particular with our finding that a FAAH-1 inhibitor, at a concentration elevating anandamide levels in these cells, also inhibits leptin-induced ROS formation. Because we could not perform experiments with MAGL inhibitors in these cells, which express hardly measurable amounts of MAGL mRNA, we instead analyzed the capability of leptin to elevate ROS levels in hypothalamic neurons from MAGL null mice, which we show to contain significantly higher amounts of 2-AG than wild type mice. Again in agreement with the existence of an inhibitory CB1-mediated tone over leptin action in the hypothalamus by ECs, we found that a concentration of leptin that showed high efficacy in cultures from wild-type mice did not produce any effect on ROS in cultures from MAGL-/- mice and that a CB1 antagonist could dose-dependently restore this effect of leptin in these cultures. Thus, we propose that pharmacologically or genetically elevated levels of endogenous AEA in mHypo-E-N41 cells or endogenous 2-AG in primary cultures of mouse hypothalamic neurons, respectively, exert tonic inhibition over leptin induction of ROS, indicating that the findings of the first part of this study might have physiological relevance. In fact, it is tempting to speculate that during physiological or pathological conditions in which hypothalamic EC levels are likewise elevated, i.e. after short term food deprivation (34) or in either genetic or high fat diet-induced obesity (2, 35, 36), a similar negative control over leptin activity by CB1 activation might...
Endocannabinoids Inhibit Leptin Function in the Hypothalamus

occur. Interestingly, a recent report published during the reviewing process of the present study (37) showed that food deprivation-induced food intake is partly dependent on PPAR-γ-mediated enhancement of agouti-related protein/neuropeptide Y signaling (which is the major system expressed in mHypoE-N41 cells), and it is tempting to speculate that such a process might be due in part to CB1 activation by ECs.

In conclusion, the results reported in this study may facilitate a better understanding of the role of ECs and CB1 receptors in leptin-mediated effects on food intake and energy storage/expenditure as well as other physiopathological functions of this hormone, such as its role in neuroinflammation (38).

Acknowledgment—We are grateful to Roberta Verde for valuable help with endocannabinoid level measurements.

References

1. Jordan, S. D., Könner, A. C., and Brüning, J. C. (2010) Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. Cell. Mol. Life Sci. 67, 3255–3273
2. Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fedzai, F., Miura, G. I., Palmiter, R. D., Sugiura, T., and Kunos, G. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822–825
3. Frederich, R. C., Hamann, A., Söllmann, B., Lowell, B. B., and Flier, J. S. (1995) Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1, 1311–1314
4. Schwartz, M. W., Peskind, E., Raskind, M., Boyko, E. J., and Porte, D., Jr. (1996) Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med. 2, 59–539
5. Diano, S., Liu, Z.W., Ruan, H. B., Kim, E., Suyama, S., Kelly, K., Gyengesi, E., Arbiser, J. L., Belsham, D. D., Sarruf, D. A., Schwartz, M. W., Bennett, A. M., Shanabrough, M., Mobbs, C. V., Yang, X., Gao, X. B., and Horvath, T. L. (2011) Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat. Med. 17, 1121–1127
6. Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., Schneider, P., Seed, B., and Tschopp, J. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489–495
7. Matés, J. M., and Sánchez-Jiménez, F. (1999) Antioxidant enzymes and their implications in pathophysiologic processes. Front. Biosci. 4, D339–D345
8. van Horssen, J., Witte, M. E., Schreibelt, G., and de Vries, H. E. (2011) Radical changes in multiple sclerosis pathogenesis. Biochem. Biophys. Acta 1812, 141–150
9. Girma, G. D., Domann, F. E., Moore, S. A., and Robbins, M. E. (2002) Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 16, 2793–2801
10. Gray, E., Ginty, M., Kemp, K., Scolding, N., and Wilkins, A. (2012) The PPAR-γ agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J. Neuroinflammation 9, 63–75
11. Chen, X., Zhang, J., and Chen, C. (2011) Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience 178, 159–168
12. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., and Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527–531
13. Panikashvili, D., Mechoulam, R., Beni, S. M., Alexandrovich, A., and Shohami, E. (2005) CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. J. Cereb. Blood Flow Metab. 25, 477–484
14. Panikashvili, D., Shein, N. A., Mechoulam, R., Trembovler, V., Kohen, R., Alexandrovich, A., and Shohami, E. (2006) The endocannabinoid 2-AG protects the blood brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22, 257–264
15. Zhang, J., and Chen, C. (2008) Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283, 22601–22611
16. Du, H., Chen, X., Zhang, J., and Chen, C. (2011) Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br. J. Pharmacol. 163, 1533–1549
17. O’Sullivan, S. E. (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152, 576–582
18. Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P., and Kaminski, N. E. (2006) Interleukin-2 suppression by 2-arachidonoylglycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70, 101–111
19. Ipaţ, P., Salvi, R., Rey, J. P., Glauser, M., Pralong, F. P., and Gaillard, R. C. (2006) Effects of cytokines on gonadotropin-releasing hormone (GnRH) gene expression in primary hypothalamic neurons and in GnRH neurons immobilized conditionally. Endocrinology 147, 1037–1043
20. Petrosoin, S., Schiano Moriello, A., Cerrato, S., Fusco, M., Puigdemont, A., De Petrocellis, L., and Di Marzo V. (2015) The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at transient receptor potential vanilloid type-1 channels. Br. J. Pharmacol. 10.1111/bph.13084
21. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumski, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., and Compton, D. R. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90
22. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., and Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97
23. Stella, N., Schweitzer, P., and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773–778
24. Blankman, J. L., Simon, G. M., and Cravatt, B. F. (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14, 1347–1356
25. Chanda, P. K., Gao, Y., Mark, L., Btsh, J., Strassle, B. W., Lu, P., Piesla, M. I., Zhang, Y.-M., Bingham, B., Uveges, A., Kowal, D., Garbe, D., Kouranova, E. V., Ring, R. H., Bates, B., Pangalos, M. N., Kennedy, J. D., Whiteside, G. T., and Samad, T. A. (2010) Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol. 79, 996–1003
26. Scholsburg, J. L., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., Thomas, E. A., Selye, D. E., Sim-Selley, L. I., Liu, Q. S., Lichtman, A. H., and Cravatt, B. F. (2010) Chronic mono-acylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113–1119
27. Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G., and Campbell, W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289, 1427–1433
28. Ding, G., Fu, M., Qin, Q., Lewis, W., Kim, H. W., Fukushima, M., Chen, Y.E., Schneider, M. D., Mangelsdorf, D. J., Evans, R. M., and Yang, Q. (2007) Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc. Res. 76, 269–279
29. Chen, T., Jin, X., Crawford, B. H., Cheng, H., Saafir, T. B., Wagner, M. B., Yuan, Z., and Ding, G. (2012) Cardioprotection from oxidative stress in the newborn heart by activation of PPARγ is mediated by catalase. Free Radic. Biol. Med. 53, 208–215
30. Matias, I., Gonthier, M. P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., Roche, R., Maj, M., Pagotto, U., Monteleone, P., and Di Marzo, V. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. *J. Clin. Endocrinol. Metab.* 91, 3171–3180

31. Pagano, C., Pilon, C., Calcagno, A., Urbanet, R., Rossato, M., Milan, G., Bianchi, K., Rizzuto, R., Bernante, P., Federspil, G., and Vettor, R. (2007) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. *J. Clin. Endocrinol. Metab.* 92, 4810–4819

32. Park, B. H., Qiang, L., and Farmer, S. R. (2004) Phosphorylation of C/EBPβ at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. *Mol. Cell. Biol.* 24, 8671–8680

33. O’Sullivan, S. E., and Kendall, D. A. (2010) Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. *Immunobiology* 215, 611–616

34. Kirkham, T. C., Williams, C. M., Pezza, F., and Di Marzo, V. (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoylglycerol. *Br. J. Pharmacol.* 136, 550–557

35. Cristino, L., Busetto, G., Imperatore, R., Ferrandino, I., Palomba, L., Silvestri, C., Petrosino, S., Orlando, P., Bentivoglio, M., Mackie, K., and Di Marzo, V. (2013) Obesity-driven synaptic remodeling affects endocannabinoid control of orexinsergic neurons. *Proc. Natl. Acad. Sci. U.S.A.* 110, E2229–E2238

36. Bisogno, T., Mahadevan, A., Coccurello, R., Chang, J. W., Allarà, M., Chen, Y., Giacovazzo, G., Lichtman, A., Cravatt, B., Moles, A., and Di Marzo, V. (2013) A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. *Br. J. Pharmacol.* 169, 784–793

37. Garretson, J. T., Teubner, B. J., Grove, K. L., Vazdarjanova, A., Ryu, V., and Bartness, T. J. (2015) Peroxisome proliferator-activated receptor γ controls ingestive behavior, agouti-related protein, and neuropeptide Y mRNA in the arcuate hypothalamus. *J. Neurosci.* 35, 4571–4581

38. Matarese, G., Carrieri, P. B., Montella, S., De Rosa, V., and La Cava, A. (2010) Leptin as a metabolic link to multiple sclerosis. *Nat. Rev. Neurol.* 6, 455–461